Percutaneous closure of atrial septal defects: immediate and mid-term results.

INTRODUCTION: The incidence of percutaneous closure of secundum atrial septal defects (ASD) and patent foramen ovale (PFO), which has become an established therapy, is constantly increasing. In this study, which is the first in the Greek literature, we present the immediate and mid-term results from this intervention in our center. METHODS: From April 2004 to April 2008, 103 patients underwent percutaneous closure of an ASD or PFO using Amplatzer closure devices. Thirty were male, the mean age was 37 +/- 15.5 years, and the mean follow-up period 21.7 +/- 14.8 months. The procedure was successful in 102 of the above patients; 69 (mean age 36.3 years +/- 17.1, 81% female) underwent secundum ASD closure, while 33 patients (mean age 39.1 +/- 10.5 years, 16 female and 17 male) underwent percutaneous closure of a PFO due to cryptogenic stroke. RESULTS: There were no major complications during the procedure (death, device embolization or need for immediate cardiac surgery). There were minor complications in 8 (7.7%) patients (bleeding at the puncture site, transient ST elevation in the inferior leads, multiple atrial and ventricular ectopics). The transient ST elevation in the inferior leads appeared in 5 patients (5%) and was probably due to air embolization. This transient complication completely resolved within 3 minutes. During the follow-up period, no patient had a major complication (cardiac rupture, device embolization, thrombus formation, thromboembolism or infective endocarditis). Most importantly, in the patients who underwent PFO closure there were no recurrences of cryptogenic stroke during the follow-up period (24.3 +/- 14.5 months). CONCLUSIONS: This study shows that using Amplatzer closure devices for atrial septal communications is both safe and effective, with sustained results over a maximum follow-up period of four years. Appropriate patient selection, as well as accurate device sizing fitting the dimensions of the defect, are important factors for the success and the safety of the method.

Modified (Valsalva graft) aortic root reimplantation for successful repair of pulmonary autograft aneurysm after Ross procedure.

Dilatation of the pulmonary autograft after the Ross procedure is a possible complication, necessitating aortic valve replacement. We present a case of a patient who developed pulmonary autograft dilatation and was treated successfully with valve-sparing aortic root reimplantation with a Valsalva graft.

Ross procedure: medium-term results.

INTRODUCTION: The Ross procedure is a safe alternative option for aortic valve replacement in selected patients. Here we present the medium-term results of our experience with this procedure. METHODS: Between December 1998 and January 2004, 21 patients (16 male, 5 female, mean age 42 years) underwent aortic valve replacement using the Ross operation. Indications for operation were aortic stenosis in 5 patients, aortic regurgitation in 5 patients, aortic stenosis and regurgitation in 9 patients, acute septic endocarditis of a native aortic valve in 1 patient and of a mechanical aortic valve in 1 patient. The root replacement technique was used in 17 patients (81%) and the subcoronary insertion technique in 4 patients (19%). RESULTS: Hospital mortality was 4.7% (1 patient) and late mortality is zero. Mean follow up duration was 4 years (range 1-6 years). On follow up all of the patients were in New York Heart Association class I. One patient developed neo-aortic root dilatation (5.1 cm) with mild neo-aortic valve regurgitation and underwent a modified David I procedure using a Valsalva graft. None of the patients had a gradient of more than 10 mmHg through the pulmonary autograft. Sixteen patients had no aortic insufficiency, while mild aortic regurgitation developed in three patients. Pulmonary valve regurgitation developed in 11 patients (range 8-75 mmHg) but only one patient (75 mmHg) developed significant asymptomatic stenosis. CONCLUSIONS: Our experience with the Ross procedure suggests that aortic root replacement with a pulmonary autograft can be performed safely in adult patients. Pulmonary homograft degeneration requiring reintervention might be a rare complication.

First human implantation of a new rotary blood pump: design of the clinical feasibility study.

Surgical treatment of heart failure is emerging as one of the most challenging clinical dilemmas for patients with end-stage cardiac failure not amenable to medical treatment. One of the most intriguing techniques is the use of implantable left ventricular assist devices (LVADs) as a bridge to recovery. The early experience from our centre has shown that even short term post-cardiotomy mechanical assistance, after heart failure surgery, improves patient outcome; thus, a clinical feasibility study was designed. The hypothesis of the study is that reparative heart failure surgery combined with postoperative mechanical support, ventricular resynchronisation where indicated, and pharmacological treatment can maximise myocardial recovery. In the study a new, implantable, magnetically levitated, rotary pump will be used as a bridge to recovery. In this manuscript the first worldwide human implantation of a new, continuous-flow LVAD, the WorldHeart Rotary Pump (Levacor, WorldHeart Inc., Oakland CA), is reported. The design and the rationale of the feasibility study, the inclusion and exclusion criteria, and the primary and secondary end points of the clinical investigation, are delineated. In addition, the design of the new rotary pump, its general principles of operation, and the implantation technique are described.